. 2020 Sep 10;45(Suppl 1):28–42. doi: 10.1111/jcpt.13224

Table 4.

HbA_1c and body weight change from head‐to‐head GLP‐1 RA trials

Trial name, time until primary endpoint	Treatment arms	Background treatments	ETD HbA_1c, % [95% CI]; P‐value	ETD body weight, kg [95% CI]; P‐value
QW vs QW
SUSTAIN 3 ³⁹ , 56 weeks	Semaglutide s.c. 1 mg	Metformin ± TZDs/SUs	−0.62 [−0.80; −0.44]; <.0001	−3.78 [−4.58; −2.98]; <.0001
SUSTAIN 3 ³⁹ , 56 weeks	Exenatide ER 2 mg	Metformin ± TZDs/SUs	−0.62 [−0.80; −0.44]; <.0001	−3.78 [−4.58; −2.98]; <.0001
SUSTAIN 7 ⁴⁰ , 40 weeks	Semaglutide s.c. 0.5 mg	Metformin	−0.40 [−0.55; −0.25]; <.0001	−2.26 [−3.02; −1.51]; <.0001
	Dulaglutide 0.75 mg		−0.40 [−0.55; −0.25]; <.0001	−2.26 [−3.02; −1.51]; <.0001
	Semaglutide s.c. 1 mg		−0.41 [−0.57; −0.25]; <.0001	−3.55 [−4.32; −2.78]; <.0001
	Dulaglutide 1.5 mg		−0.41 [−0.57; −0.25]; <.0001	−3.55 [−4.32; −2.78]; <.0001
QW vs QD/BID
AWARD‐1 ¹⁵ , 26 weeks	Dulaglutide 0.75 mg	Pioglitazone ± metformin	(−1.30 ± 0.06 ^a )	(0.20 ± 0.29 ^a )
	Dulaglutide 1.5 mg		(−1.51 ± 0.06 ^a )	(−1.30 ± 0.29 ^a )
	Exenatide 10µg BID		(−0.99 ± 0.06 ^a )	(−1.07 ± 0.29 ^a )
	Placebo		(−0.46 ± 0.08 ^a )	(1.24 ± 0.37 ^a )
AWARD‐6 ³⁶ , 26 weeks	Dulaglutide 1.5 mg	Metformin	−0.06 [0.19; 0.07]; <.0001 ^b	−0.71 [0.17; 1.26]; .011
AWARD‐6 ³⁶ , 26 weeks	Liraglutide 1.8 mg (QD)	Metformin	−0.06 [0.19; 0.07]; <.0001 ^b	−0.71 [0.17; 1.26]; .011
DURATION‐5 ³⁷ , 24 weeks	Exenatide ER 2 mg	Metformin, SUs, TZDs	−0.7 [−0.9; −0.4]; <.01	−0.95 [−1.9; 0.01]; NR ^†
DURATION‐5 ³⁷ , 24 weeks	Exenatide 10 µg BID	Metformin, SUs, TZDs	−0.7 [−0.9; −0.4]; <.01	−0.95 [−1.9; 0.01]; NR ^†
DURATION‐6 ³⁸ , 26 weeks	Exenatide ER 2 mg	Metformin, SU, metformin + SU, or metformin + pioglitazone	−0.21 [0.08; 0.33]; .0018	0.90 [0.39; 1.40]; .0005
DURATION‐6 ³⁸ , 26 weeks	Liraglutide 1.8 mg (QD)	Metformin, SU, metformin + SU, or metformin + pioglitazone	−0.21 [0.08; 0.33]; .0018	0.90 [0.39; 1.40]; .0005
SUSTAIN 10 ³⁵ , 30 weeks	Semaglutide s.c. 1 mg	1–3 OADs	−0.69 [−0.82; −0.56]; < .0001	−3.83 [−4.57; −3.09]; <.0001
SUSTAIN 10 ³⁵ , 30 weeks	Liraglutide 1.2 mg (QD)	1–3 OADs	−0.69 [−0.82; −0.56]; < .0001	−3.83 [−4.57; −3.09]; <.0001

BID, twice‐daily; CI, confidence interval; ETD, estimated treatment difference; exenatide ER, exenatide extended‐release; exenatide ER AI, exenatide ER auto‐injectable; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HbA_1c, glycated haemoglobin; NR, not reported; QD, once‐daily; QW, once‐weekly; s.c., subcutaneous; SU, sulphonylurea; TZD, thiazolidinedione.

^{^a}

Least squares mean difference from baseline ± standard error.

^{^b}

Significance for non‐inferiority; ^†statistical significance not reported at Week 24.